Unity Biotechnology, Inc. (UBX): Price and Financial Metrics


Unity Biotechnology, Inc. (UBX): $0.85

0.06 (+7.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add UBX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

UBX Stock Price Chart Interactive Chart >

Price chart for UBX

UBX Price/Volume Stats

Current price $0.85 52-week high $5.09
Prev. close $0.79 52-week low $0.70
Day low $0.79 Volume 235,300
Day high $0.85 Avg. volume 778,460
50-day MA $1.00 Dividend yield N/A
200-day MA $1.89 Market Cap 58.79M

Unity Biotechnology, Inc. (UBX) Company Bio


Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is based in Brisbane, California.


UBX Latest News Stream


Event/Time News Detail
Loading, please wait...

UBX Latest Social Stream


Loading social stream, please wait...

View Full UBX Social Stream

Latest UBX News From Around the Web

Below are the latest news stories about Unity Biotechnology Inc that investors may wish to consider to help them evaluate UBX as an investment opportunity.

UNITY posts 24-week data from Phase 1 trial for UBX1325 in vascular eye diseases

UNITY Biotechnology <> announced 24-week data from its Phase 1 study for UBX1325 in patients with diabetic macular edema ((DME)) and wet age-related macular degeneration (wet…

Seeking Alpha | February 14, 2022

UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) showed improvement in visual acuity through 24 weeks following single dose of UBX1325 Phase 2 clinical studies of UBX1325 currently enrolling patients with DME and wAMD SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company de

Yahoo | February 14, 2022

H.C. Wainwright Thinks Unity Biotechnology’s Stock is Going to Recover

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $12.00. The company's shares closed last Monday at $1.02, close to its 52-week low of $1.00. According to TipRanks.com, Fein is ranked 0 out of 5 stars with an average return of -3.2% and a 34.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals, Inc., and Deciphera Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $6.

Christine Brown on TipRanks | February 7, 2022

Mizuho Securities Thinks Unity Biotechnology’s Stock is Going to Recover

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $7.00. The company's shares closed last Friday at $1.02, close to its 52-week low of $1.00. According to TipRanks.com, Syed is ranked 0 out of 5 stars with an average return of -14.1% and a 37.5% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $5.00 average price target, implying a 371.

Catie Powers on TipRanks | February 4, 2022

Anti-aging company Unity Biotechnology to axe half its staff, focus on eye drugs

The quest to ease the pain of aging baby boomers and future generations hasn't translated into much clinical success. But as pioneering aging disease companies switch gears, startups continue to jump in.

Yahoo | February 3, 2022

Read More 'UBX' Stories Here

UBX Price Returns

1-mo N/A
3-mo -17.48%
6-mo -66.40%
1-year -80.64%
3-year -90.48%
5-year N/A
YTD -41.78%
2021 -72.14%
2020 -27.32%
2019 -55.66%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6938 seconds.